CLINICAL TRIALS PROFILE FOR NASACORT

All Clinical Trials for NASACORT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00132925 ↗	An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis	Completed	Sanofi	Phase 3	2003-11-01	The purposes of this study are: - To demonstrate the efficacy of once daily administration of Nasacort AQ 110 µg compared with placebo in children 2-5 years of age with perennial allergic rhinitis; and - To assess the safety of Nasacort AQ 110 µg in children 2-5 years of age.
NCT00344942 ↗	Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults	Terminated	Sanofi	Phase 3	2006-04-01	To demonstrate the superiority of the clinical efficacy of 12 weeks' treatment with Nasacort versus placebo in adult patients presenting with Chronic Non Allergic and Non Infectious Rhinitis
NCT00449072 ↗	Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)	Completed	Sanofi	Phase 4	2007-03-01	The primary objective of the study was to characterize the difference in prepubescent growth velocity in children 3 to 9 years of age with perennial allergic rhinitis (PAR) treated with triamcinolone acetonide (TAA) nasal spray (NASACORT® AQ 110 μg treatment group) or placebo (NASACORT® AQ placebo group) for 12-months. The secondary objectives were to compare the following in prepubertal participants treated with TAA nasal spray versus placebo: - the 24-hour urinary free cortisol levels and the cortisol/creatinine ratio (to measure the Hypothalamic-Pituitary Adrenal [HPA] axis function) - the rate of treatment-emergent-adverse-events (TEAE) - global efficacy rated by the investigator and the participant separately - the rate of use of rescue medication during the study
NCT00987233 ↗	A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis	Completed	Apotex Inc.	Phase 3	1969-12-31	A randomized, double-blind, placebo-controlled parallel-group study, comparing the bioequivalence of triamcinolone acetonide aqueous nasal spray (Apotex, Inc.) to that of Nasacort® AQ nasal spray (Sanofi-Aventis Pharmaceutical Products, Inc.) in the treatment of seasonal allergic rhinitis.
NCT01154153 ↗	Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis	Completed	Sanofi	Phase 4	2010-06-01	The primary objective was to evaluate the effect of a 6-week treatment with TAA-AQ (110 μg) and TAA-AQ (220 μg) once daily (QD) versus placebo on hypothalamic-pituitary-adrenal (HPA) axis function as measured by serum cortisol AUC(0-24 hr) in children (>=2 to
NCT02877485 ↗	The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation	Completed	Stanford University	Phase 4	2016-08-01	The purpose of this project is to determine if intranasal corticosteroids have an effect on nasal obstruction in patients with nasal septal deviation.

Clinical Trial Conditions for NASACORT

Condition Name

Condition Name for NASACORT
Intervention	Trials
Rhinitis, Allergic, Perennial	2
Rhinitis Allergic	1
Rhinitis, Allergic, Perennial and/or Seasonal	1
Seasonal Allergic Rhinitis	1

Condition MeSH

Condition MeSH for NASACORT
Intervention	Trials
Rhinitis	6
Rhinitis, Allergic	5
Rhinitis, Allergic, Perennial	4
Nasal Obstruction	1

Clinical Trial Locations for NASACORT

Trials by Country

Trials by Country for NASACORT
Location	Trials
United States	12
France	1
Canada	1

Trials by US State

Trials by US State for NASACORT
Location	Trials
New Jersey	3
California	2
Texas	1
South Carolina	1
North Carolina	1

Clinical Trial Progress for NASACORT

Clinical Trial Phase

Clinical Trial Phase for NASACORT
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	4
N/A	1

Clinical Trial Status

Clinical Trial Status for NASACORT
Clinical Trial Phase	Trials
Completed	6
Unknown status	1
Terminated	1

Clinical Trial Sponsors for NASACORT

Sponsor Name

Sponsor Name for NASACORT
Sponsor	Trials
Sanofi	5
Apotex Inc.	1
Stanford University	1

Sponsor Type

Sponsor Type for NASACORT
Sponsor	Trials
Industry	6
Other	2

NASACORT (TRIAMCINOLONE ACETONIDE) CLINICAL TRIALS UPDATE, MARKET ANALYSIS AND PROJECTION

Last updated: May 3, 2026

What is NASACORT and what are the key commercial anchors?

NASACORT is triamcinolone acetonide (a corticosteroid) marketed as intranasal therapy for allergic rhinitis. The product is long-established, and the commercial value is driven by (1) dosing convenience, (2) broad indication fit for allergic rhinitis, and (3) entrenched payer and pharmacy channel placement versus less established intranasal corticosteroids.

Core commercial realities affecting projections

• Market structure: Intranasal corticosteroids (INCS) compete in a crowded category with frequent generic substitution in many geographies and payer formularies.
• Drivers: Persistent allergic rhinitis prevalence and seasonal repeat use.
• Constraints: Generic erosion and pricing pressure are the dominant forces; new clinical differentiation must be meaningful to overcome formulary inertia.

What do current clinical trials show for NASACORT?

A complete, audit-grade “clinical trials update” requires access to a contemporaneous registry snapshot (e.g., ClinicalTrials.gov with status, design, endpoints, and expected timelines). This request cannot be completed without that live trial data.

No clinical-trial specifics are provided here, so this report does not cite trial identifiers, patient counts, or readouts.

How big is the intranasal corticosteroid opportunity and where does NASACORT sit?

NASACORT competes within the INCS class used for allergic rhinitis management. The addressable market is shaped by:

• Seasonal and perennial allergic rhinitis burden
• Switching dynamics across INCS options
• Payer preference for formulary-listed agents and lower acquisition costs
• OTC vs prescription channel mix, which varies by market

NASACORT positioning (category economics)

• When generic triamcinolone acetonide intranasal products are available, pricing tends toward cost-led competition, lowering the incremental revenue impact of brand loyalty.
• To support premium economics, a NASACORT-like franchise must deliver differentiation on device, dosing convenience, or tolerability that payers and prescribers can translate into measurable adherence or outcomes.

What competitive set matters most for NASACORT?

For planning purposes, the competitive set is the INCS cohort plus select alternatives that displace INCS in real-world prescribing:

• Other INCS (e.g., fluticasone-based, budesonide-based)
• Adjuncts for allergic rhinitis where prescribers step up care (e.g., antihistamines, combination sprays)

Practical implication for projections: NASACORT volumes tend to track category volume growth and formulary placement, while revenue tends to track net price and generic mix.

What market trends will move revenue for NASACORT in the next 3 to 5 years?

Trend 1: Net price compression from generic availability

• Intranasal steroid markets typically show sustained downward pressure where AB-rated products expand.
• Revenue forecasts must be built on net price and reimbursement shifts, not list price.

Trend 2: Formulary management that favors acquisition cost

• Payers narrow to a limited formulary set.
• Switching is common when payer step-therapy or tier changes occur.

Trend 3: Adherence and device preference

• Device ergonomics and dosing frequency influence persistence.
• Outcomes depend on patient technique, which is where product usability matters.

Trend 4: Seasonality

• Revenue is seasonally weighted.
• Forecasting must incorporate quarterly seasonal curves, not linear growth.

What is the projected market path for NASACORT (base, upside, downside)?

A projection requires baseline market size, NASACORT share, net pricing assumptions, and formulary/generic timelines. Those inputs are not provided here and cannot be derived without citing specific market datasets.

Accordingly, no numerical revenue or unit projection is issued.

What should investors and R&D teams focus on given NASACORT’s lifecycle stage?

Even without new clinical readouts, decision-relevant planning still rests on:

• Channel strategy (brand protection vs generic competition)
• Device and formulation improvements that can justify formulary re-qualification
• Evidence generation aimed at payer-facing endpoints (adherence proxy, symptom control, persistence) if differentiation is pursued

Key Takeaways

• NASACORT is an established intranasal triamcinolone franchise operating in a crowded INCS market where generic and formulary forces dominate revenue outcomes.
• A definitive clinical-trials update cannot be delivered without a current registry dataset and trial-level details.
• Numerical market projections cannot be produced without baseline market sizing, NASACORT share, and net price trajectory inputs.

FAQs

1. Is NASACORT still expanding clinically?
   It depends on current registry activity and trial-level evidence; those specifics are not included in this report.

2. What most drives NASACORT revenue: volume or net price?
   In INCS categories, net price and reimbursement generally dominate due to generic substitution and payer tiering.

3. Do device differences matter for intranasal steroids?
   Yes. For payer and prescriber adoption, usability and dosing convenience can affect adherence and persistence.

4. How should seasonal demand be handled in forecasting?
   Use quarterly seasonal curves rather than linear growth assumptions.

5. What would justify a premium strategy for NASACORT-like products?
   Clear, payer-relevant differentiation such as adherence/persistence benefits or meaningful tolerability improvements supported by trial evidence.

---

References (APA)

[1] ClinicalTrials.gov. (n.d.). Search results for triamcinolone acetonide nasal. U.S. National Library of Medicine. (No trial-level data were extracted for this report.)